|
NOP-1A
|
DB15208 |
[NOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A).] |
|
Capromorelin
|
DB15205 |
[Capromorelin is under investigation in clinical trial NCT00527046 (Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults).] |
|
Fosravuconazole
|
DB15204 |
[Fosravuconazole is under investigation in clinical trial NCT03378661 (BENDITA BEnznidazole New Doses Improved Treatment and Associations).] |
|
Esaxerenone
|
DB15207 |
[Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension).] |
|
Uprifosbuvir
|
DB15206 |
[Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)).] |
|
Norbixin
|
DB15201 |
[Norbixin is under investigation in clinical trial NCT03820245 (Effect of Short-term Annatto Carotenoids Supplementation on Oxidative Stress Status in Healthy Individuals).] |
|
Bixalomer
|
DB15200 |
[Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).] |
|
JNJ-26489112
|
DB15203 |
[JNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy).] |
|
Fluoroacetic acid F-18
|
DB15202 |
[Fluoroacetic acid F-18 is under investigation in clinical trial NCT01320787 (18-F-Fluoroacetate as PET Imaging Agent).] |
|
2-Oxo-4-Methylpentanoic Acid
|
DB03229 |
|
|
Nicotinamide Mononucleotide
|
DB03227 |
[3-Carbamoyl-1-beta-D-ribofuranosyl pyridinium hydroxide-5'phosphate, inner salt. A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN. [PubChem]] |
|
5-[Bis-2(Chloro-Ethyl)-Amino]-2,4-Dintro-Benzamide
|
DB03228 |
|
|
N-(Chlorophenyl)-N'-Hydroxyguanidine
|
DB04559 |
|
|
Inotuzumab ozogamicin
|
DB05889 |
[Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg ([DB00056]), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent [A20352]. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy [A20353].] |
|
MEM 1414
|
DB05888 |
[MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials. MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed.] |
|
3-[(1s)-1-(Dimethylamino)Ethyl]Phenol
|
DB04556 |
|
|
D-Tryptophan
|
DB03225 |
[Tryptophan is one of the 20 standard amino acids, as well as an essential amino acid in the human diet. It is encoded in the standard genetic code as the codon UGG. The D-stereoisomer is occasionally found in naturally produced peptides (for example, the marine venom peptide contryphan). The distinguishing structural characteristic of tryptophan is that it contains an indole functional group. It is an essential amino acid as defined by its growth effects on rats.] |
|
Trifluoroethanol
|
DB03226 |
[A non-aqueous co-solvent that serves as tool to study protein folding. It is also used in various pharmaceutical, chemical and engineering applications.] |
|
Arachidonic Acid
|
DB04557 |
[An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, brain, and glandular organs, and is a constituent of animal phosphatides. It is formed by the synthesis from dietary linoleic acid and is a precursor in the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. [PubChem]] |
|
TAFA-93
|
DB05887 |
[TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary artery disease.] |
